{
    "organizations": [],
    "uuid": "3a450c259c5402f561453fcdf3d966257c0b43ce",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-compugen-announces-exclusive-licen/brief-compugen-announces-exclusive-license-agreement-with-medimmune-idUSFWN1RF06B",
    "ord_in_thread": 0,
    "title": "BRIEF-Compugen Announces Exclusive License Agreement With Medimmune",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 2 (Reuters) - Compugen Ltd:\n* SEC FILING * CO ALSO ELIGIBLE TO RECEIVE UP TO $200 MILLION IN DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES ON FUTURE PRODUCT SALES Source text ( bit.ly/2GsywkV ) Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-04-02T20:44:00.000+03:00",
    "crawled": "2018-04-03T16:02:49.038+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "compugen",
        "ltd",
        "sec",
        "filing",
        "co",
        "also",
        "eligible",
        "receive",
        "million",
        "development",
        "regulatory",
        "commercial",
        "milestone",
        "future",
        "product",
        "sale",
        "source",
        "text",
        "company",
        "coverage"
    ]
}